Exciting new research is revealing that psychedelic drugs, such as psilocybin and MDMA, may offer significant benefit for patients struggling at the end of life and those beset by major depressions and treatment-resistant post-traumatic stress.
A conference at the University of Washington School of Law, on October 27, 2017, brings together doctors, scientific researchers, attorneys and ethicists to consider the medical, legal and ethical implications of this evolving research.
Confirmed speakers include:
- Dan Abrahamson, Senior Legal Advisor, Drug Policy Alliance’s Office of Legal Affairs, Oakland, CA
- Ira Byock, M.D., Founder and Chief Medical Officer, Providence Institute for Human Caring, Torrance, CA
- Rick Doblin, Founder and Executive Director of Multidisciplinary Association for Psychedelic Studies, Boston, MA
- Representative Roger Goodman, Washington State Legislature, Kirkland, WA
- Sam Kamin, marijuana law reform expert and Slate series author of “Altered States: Inside Colorado’s Marijuana Economy,” Professor of Law, University of Denver, Denver, CO
- Patricia Kuszler, Charles I. Stone Professor of Law, University of Washington School of Law, Seattle, WA
- Don Lattin, award-winning author and journalist, author of Changing our Minds—Psychedelic Sacraments and the New Psychotherapy, adjunct faculty, Graduate School of Journalism, University of California at Berkeley, CA
- Lynn Mehler, partner, Hogan Lovells, Pharmaceutical and Biotechnology practice, Washington, DC
- Leanna Standish, Ph.D., School of Naturopathic Medicine, Bastyr University, Seattle, WA
- Kathryn Tucker, Executive Director, End of Life Liberty Project
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.